A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin’s lymphoma
Year: 2020
Type: article
Study design: Clinical Trial
Source: Annals of Hematology
Institutions: Hanyang University Guri Hospital, Hanyang University, Yonsei University, Severance Hospital, National Cancer Center, Yonsei University Health System, National Cancer Center Hospital, Asan Medical Center, University of Ulsan, Korea Institute of Radiological and Medical Sciences, Gachon University, Gachon University Gil Medical Center, Samsung Medical Center, Sungkyunkwan University, Inje University Busan Paik Hospital, National Health Insurance Service Ilsan Hospital, Keimyung University Dongsan Medical Center, Keimyung University, Chung-Ang University Hospital, Chung-Ang University, Seoul National University, Seoul National University Hospital, Soonchunhyang University, Soonchunhyang University Hospital Seoul, Dong-A University Hospital, Dong-A University, Ulsan University Hospital
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: National Cancer Center
OpenAlex ID: W2997754832